WEIGHT & METABOLIC COMPARISON
Retatrutide, Tirzepatide, and Cagrilintide are the leading peptides studied for weight and metabolic research—but they differ in receptor targets, evidence stage, and research emphasis. Compare them side by side.
COMPARE THE PROFILES
Highlight one compound to see its relative profile across the key research dimensions. Bars reflect studied research emphasis and evidence stage, not a guarantee of results.
Dual Agonist
A dual GIP + GLP-1 agonist and an FDA-approved medication in its clinical formulations. The most clinically established of the three, studied for weight, glucose, and body composition.
Triple Agonist
A triple GLP-1 + GIP + glucagon agonist reporting the largest weight-loss effects of the three in trials. Phase 3 complete (not yet approved), with roughly two years of research-market use.
Amylin Agonist
A long-acting amylin receptor agonist studied for satiety through a different pathway than the incretins. Phase 3 data reported, but real-world use is still developing.
WHY RESEARCHERS COMPARE THEM
From dual (Tirzepatide) to triple (Retatrutide) incretin agonism, plus the separate amylin pathway (Cagrilintide).
One is FDA-approved, two completed Phase 3—the comparison shows how evidence maturity differs even among leading compounds.
Each is rated with the same Evidence Framework, so the bars reflect a consistent standard rather than marketing.
Bars reflect each compound's studied research emphasis and evidence stage relative to the other two—not absolute effect sizes or a promise of results. Retatrutide and Cagrilintide are investigational and not FDA-approved. All materials are offered strictly for laboratory and research use. See each compound page for its full Evidence Snapshot.
